太平洋给予心脉医疗买入评级，心脉医疗：增长动力储备充足，出海大步向前

Group 1 - The core viewpoint of the report is that Xinpai Medical (688016.SH) is rated as a buy due to its promising growth prospects and strong revenue performance [1] - The company has shown significant progress in research and development, indicating a solid reserve of growth momentum for the future [1] - Xinpai Medical's revenue nearly doubled year-on-year in the first half of the year, reflecting successful international expansion [1] - The gross profit margin has been affected by product price reductions and increased expenses [1] Group 2 - The report highlights potential risks including price reduction from centralized procurement, slow bidding process, and underperformance in consumable promotion [1]